Continuous Administration of Subcutaneous Levodopa/Carbidopa (ND0612) Demonstrated Comparable Levodopa Pharmacokinetics to Levodopa/Carbidopa Intestinal Gel (LCIG)

被引：0

作者：

Adar, Liat ^{[1
]}

Minei, Tamar Rachmilewitz ^{[1
]}

Cohen, Yael ^{[1
]}

Oren, Sheila ^{[1
]}

机构：

[1] NeuroDerm Ltd, Rehovot, Israel

来源：

NEUROLOGY | 2017年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S4.003

引用

页数：2

共 50 条

[1] Pharmacokinetics-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612
Birnberg, T.
Adar, L.
Poewe, W.
Nyholm, D.
Bjornsson, M.
Karlsson, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 608 - 608
[2] Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)
Adar, L.
Minei, T. Rachmilewitz
Cohen, Y.
Oren, S.
MOVEMENT DISORDERS, 2017, 32
[3] The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
LeWitt, Peter A.
Stocchi, Fabrizio
Arkadir, David
Caraco, Yoseph
Adar, Liat
Perlstein, Itay
Case, Ryan
Giladi, Nir
FRONTIERS IN NEUROLOGY, 2022, 13
[4] Identification of the Carbidopa Concentration in Subcutaneously Administered ND0612 (Levodopa/Carbidopa) that Provides Optimal Levodopa Bioavailability
Adar, Liat
Rachmilewitz, Tami
Oren, Sheila
NEUROLOGY, 2017, 88
[5] Relative bioavailability of levodopa given as a subcutaneous infusion with ND0612 versus oral IR levodopa/carbidopa
Adar, L.
Vostokova, N.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 165 - 165
[6] Administration of continuous subcutaneous carbidopa improves levodopa pharmacokinetics
Yacoby-Zeevi, O.
Oren, S.
LeWitt, P.
MOVEMENT DISORDERS, 2011, 26 : S284 - S284
[7] Polyneuropathy in patients with continuous levodopa/carbidopa intestinal gel (LCIG) infusion
Pauls, K.
Toppila, J.
Koivu, M.
Eerola-Rautio, J.
Udd, M.
Pekkonen, E.
MOVEMENT DISORDERS, 2019, 34 : S73 - S74
[8] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
Adar, Liat
Vostokova, Natalia
NEUROLOGY, 2023, 100 (17)
[9] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
Adar, L.
Vostokova, N.
MOVEMENT DISORDERS, 2022, 37 : S438 - S439
[10] Quality of life with continuous subcutaneous levodopa/carbidopa infusion: Exploratory findings from the ND0612 BeyoND study
Espay, Alberto
Yardeni, Tami
Adar, Liat
Case, Ryan
Poewe, Werner
Isaacson, Stuart
MOVEMENT DISORDERS, 2023, 38 : S16 - S16

← 1 2 3 4 5 →